Crohn's Disease Therapeutics Market Size and Competitive Analysis by 2031

[Research Report] The Crohn's disease therapeutics market was valued at US$ 9.68 billion in 2023 and is projected to reach US$ 13.33 billion by 2031. It is expected to register a CAGR of 4.1% in 2023–2031.

Market Insights and Analyst View:

Crohn's disease is a chronic inflammatory condition that primarily affects the gastrointestinal tract. It commonly affects the end part of the small intestine and the beginning of the large intestine. The disease is characterized by the inflammation of the digestive tract lining, leading to symptoms such as abdominal pain, diarrhea, and malnutrition. The growing Crohn's disease therapeutics market size is attributed to the increasing prevalence of diseases in Western countries, particularly the US. In addition, strategic initiatives by companies to stay competitive in the market are fueling market growth. A significant increase in the usage of advanced medical devices is likely to bring new Crohn's disease therapeutics market trends during the forecast period.

Growth Drivers and Challenges:

Crohn's disease is an irritable bowel syndrome, a chronic inflammatory bowel disorder with no specific cure. The exact etiology of this disease is not known, but the condition is mainly the result of an inappropriate immune response in the bowel to drugs, toxins, infections, and intestinal microbes, among other environmental factors, especially in a genetically susceptible host. According to National Library of Medicine, Crohn's disease (CD) is more common in developed countries in the West, especially in North American and northern European countries, and New Zealand. The disease onset is most common in individuals aged 15–30 years and 40–60 years, and it is more prominent in urban areas. The incidence of this disease is high in people from northern European countries and Jewish descent, i.e., 3.2/1,000. However, recent studies have shown a significant increase in incidence in Asia, Africa, and Australasia as well due to rapid industrialization in the region. Thus, the staggering prevalence of Crohn's disease in the respective region boosts the Crohn's disease therapeutics market.

According to National Institute of Health, Crohn's disease poses a significant economic burden with direct healthcare costs of approximately US$ 3,500 per patient per year in Europe. The disease affects approximately 322 people per 100,000. However, the prevalence rates may vary depending on countries to countries. More than 50% of patients with Crohn's disease may not be formally diagnosed, or they may show symptoms that are the same as those of other digestive tract diseases. Crohn's disease is more common in women as compared to men, i.e., it may affect three times more women than men.

Companies involved in drug development for irritable bowel syndrome are taking constructive steps to implement awareness programs with an aim to effectively cope with this syndrome by spreading awareness about symptoms, diagnoses, and treatments. In 2018, Allergan PLC and Ironwood, in collaboration, launched an Interactive Digital Destination platform to encourage sufferers to get educated and take action against digestive tract disorders. Thus, the rising prevalence of irritable bowel syndrome drives the Crohn's disease therapeutics market growth.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Crohn's Disease Therapeutics Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Report Segmentation and Scope:

The Crohn's disease therapeutics market analysis has been carried out by considering the following segments: drug type, distribution channel, and geography. By drug class, the market is segmented into anti-inflammatory drugs, immune system suppressors, antibiotics, biologics, anti-diarrheal, and pain relievers. The biologics segment held the largest market share in 2023. The anti-inflammatory drugs segment is expected to record the highest CAGR during 2023–2031.

Based on end user, the market is divided into hospital pharmacies, clinical pharmacies, and online others. The hospital pharmacy segment accounted for the largest Crohn's disease therapeutics market share in 2023. In terms of geography, the scope of the Crohn's disease therapeutics market report entails North America (US, Canada, and Mexico), Europe (Spain, UK, Germany, France, Italy, and Rest of Europe), Asia Pacific (South Korea, China, Japan, India, Australia, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Regional Analysis:

North America is the largest contributor to the global Crohn's disease therapeutics market growth. Asia Pacific is estimated to record the highest CAGR in the market during 2023–2031. The market progress in North America is attributed to the growing incidence of chronic diseases, technological advancements and access to technologically advanced medical products, the surging geriatric population, and the presence of key market players involved in new and existing product developments. The US held the largest Crohn's disease therapeutics market share in North America in 2023.

Crohns Disease Therapeutics

Crohn's Disease Therapeutics Market Regional Insights

The regional trends and factors influencing the Crohn's Disease Therapeutics Market throughout the forecast period have been thoroughly explained by the analysts at The Insight Partners. This section also discusses Crohn's Disease Therapeutics Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Crohn's Disease Therapeutics Market Report Scope

Crohn's Disease Therapeutics Market Players Density: Understanding Its Impact on Business Dynamics

The Crohn's Disease Therapeutics Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the Crohn's Disease Therapeutics Market are:

1. ABBVIE, INC.
2. JOHNSON AND JOHNSON PRIVATE LIMITED
3. GLAXOSMITHKLINE PLC
4. MERCK AND CO., INC.
5. NOVARTIS AG

Disclaimer: The companies listed above are not ranked in any particular order.

Industry Developments and Future Opportunities:

The Crohn's disease therapeutics market forecast is estimated on the basis of various secondary and primary research findings, such as key company publications, association data, and databases. As per the company press releases, key developments by major players operating in the Crohn's disease therapeutics market are listed below:

• In 2023, the US Food and Drug Administration (FDA) approved the first oral pill—Rinvoq (upadacitinib)—to treat moderate-to-severe Crohn's disease. Rinvoq is meant to treat adult patients who could not be treated successfully with drug candidates blocking tumor necrosis factor (TNF).
• In 2022, the FDA approved Skyrizi for the treatment of adults with moderate-to-severe active Crohn's disease cases.
• In 2021, AbbVie Inc. announced the initiation of the Phase 3 trial of risankizumab for the treatment of Crohn's disease. Risankizumab is a humanized monoclonal antibody that selectively targets the interleukin-23 (IL-23) pathway. The trial is aimed at evaluating the efficacy and safety of risankizumab in patients with moderate-to-severe Crohn's disease.
• In 2021, Takeda Pharmaceutical Company Limited announced the initiation of the Phase 3 trial of the oral compound TAK-721 for the treatment of Crohn's disease. TAK-721 is a selective antagonist of the chemokine receptor CXCR3. The trial is aimed at evaluating the efficacy and safety of TAK-721 in patients with moderate-to-severe Crohn's disease.

Competitive Landscape and Key Companies:

Abbvie, Inc.; Johnson and Johnson Private Limited; GlaxoSmithKline Plc; Merck and Co., Inc.; Novartis Ag; Celgene Corporation; Genentech; Pfizer Inc.; Nestle Health Science; and Boehringer Ingelheim GmbH are among the prominent players profiled in the Crohn's disease therapeutics market report. In addition, several other players have been studied and analyzed during the study to get a holistic view of the market and its ecosystem. These companies focus on geographic expansions and new product launches to meet the growing demand from consumers worldwide and expand their product range with specialty portfolios. Their global presence allows them to serve a large customer base, subsequently facilitating market expansion.